BIOVAIL DOWN 21% AFTER COURT RULING ON WELLBUTRIN

Shares of Biovail Corp. are down sharply Wednesday after a U.S. court granted Anchen Pharmaceuticals Inc. a key part of a summary judgment motion in the Wellbutrin XL patent infringement case. BMO Capital analyst Christine Charette said in a note to clients that the court found Anchen didn't infringe Biovail's Wellbutrin XL patent. While the court didn't grant summary judgment regarding patent invalidity, she said that is "not relevant" at this point.
Market Watch